Quick Takeaways
- This page summarizes Lei Meng's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
- 2 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 24 Jan 2024, 18:55.
Lei Meng - 22 Jan 2024 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)
- Role
- Director
- Signature
- LEI MENG, /s/ Adam Veness, as attorney-in-fact for Lei Meng
- Issuer symbol
- DNTH
- Transactions as of
- 22 Jan 2024
- Net transactions value
- +$39,998,163
- Form type
- 4
- Filing time
- 24 Jan 2024, 18:55:26 UTC
- Previous filing
- 13 Sep 2023
- SEC
- View on sec.gov
Quoteable Key Fact
"Lei Meng filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 24 Jan 2024."
What Changed
- Previous filing in this sequence was filed on 13 Sep 2023.
- Current net transaction value: +$39,998,163.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DNTH | Common Stock | Award | $18,000,000 | +1,500,000 | +123% | $12.00 | 2,717,554 | 22 Jan 2024 | See footnote | F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DNTH | Pre-Funded Warrants (Right to Buy) | Award | $21,998,163 | +1,833,333 | $12.00 | 1,833,333 | 22 Jan 2024 | Common Stock | 1,833,333 | $0.001000 | See footnote | F2, F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Consists of an aggregate of 1,500,000 shares of common stock purchased by clients of Avidity Partners Management LP from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). |
| F2 | The reported securities are held by clients of Avidity Partners Management LP and may be deemed to beneficially owned by (i) Avidity Partners Management LP, (ii) Avidity Partners Management (GP) LLC, the general partner of Avidity Partners Management LP and (iii) each of David Witzke and Michael Gregory, the managing members of Avidity Partners Management (GP) LLC. Lei Meng, an employee of Avidity Partners Management LP, is a director of the Issuer. Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Mr. Witzke and Mr. Gregory may be considered directors by deputization due to their affiliation with Ms. Meng. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its, his or her pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| F3 | Consists of Pre-Funded Warrants to purchase up to an aggregate of 1,833,333 shares of common stock purchased by clients of Avidity Partners Management LP from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Exchange Act. |
| F4 | The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. |